

## Документы

Mohammad, B.I.<sup>a</sup>, Hadi, N.R.<sup>b</sup>, Singh, R.B.<sup>c</sup>, Shastun, S.<sup>d</sup>, Sharmanov, T.<sup>e</sup>, Tazhibayev, S.<sup>e</sup>, Gumarova, L.<sup>f</sup>  
**Angiotensin-receptor neprilysin inhibitor LCZ696; a novel therapy for heart failure**  
(2016) *Current Trends in Cardiovascular Research*, pp. 183-188.

<sup>a</sup> College of Pharmacy, University of Al Qadisiyah, Al Diwaniyah, Qadisiyyah Province, Iraq

<sup>b</sup> Department of Pharmacology, Faculty of Medicine, Kufa University, Najaf, Iraq

<sup>c</sup> Halberg Hospital and Research Institute, Moradabad, India

<sup>d</sup> People's Friendship University of Russia, Moscow, Russian Federation

<sup>e</sup> Kazakh Academy of Nutrition, Almaty, Kazakhstan

<sup>f</sup> Al-Farabi Kazakh National University, Almaty, Kazakhstan

## Пристатейные ссылки

- **The “Heart Disease and Stroke Statistics - 2014 Update”**  
(2014) *Circulation*, 129, pp. e28-e292.  
Published online before print December 18, 2013
- Hristova, K., Singh, R.B., Fedacko, J., Toda, E., Kumar, A., Saxena, M., Baby, A., Wilson, D.W.  
**Causes and risk factors of congestive heart failure in India**  
(2013) *World Heart J.*, 5, pp. 13-20.
- Fedacko, J., Singh, R.B., Gupta, A., Hristova, K., Toda, E., Kumar, A.  
**Inflammatory mediators in chronic heart failure in North India**  
(2014) *Acta Cardiol*, 69, pp. 391-398.
- **The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC**  
(2012) *Eur. J. Heart Fail.*, 14, pp. 803-869.
- McMurray, J.V., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R.  
**Angiotensin-neprilysin inhibition versus enalapril in heart failure**  
(2014) *N. Engl. J. Med*, 371, pp. 993-1004.
- Kumar, A., Singh, R.B., Saxena, M., Niaz, M.A., Josh, S.R., Chattopadhyay, P., Mechirova, V., Chopra, R.  
**Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study**  
(2007) *Acta Cardiol.*, 62, pp. 349-354.
- Singh, R.B., Hristova, K., El-Kilany, G., Takahashi, T., Shehab, A., Chaves, H., Wilson, D.W., Gupta, R.  
**Nutritional modulators of chronic heart failure**  
(2015) *The Open Nutra J.*, 8.
- Mortensen, S.A., Rosenfeldt, F., Kumar, A., Dolliner, P., Filipiak, K.J., Pella, D., Alehagen, U., Littarru, G.P.

**The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from QSYMBIO: A randomized double blind trial**  
(2014) *JACC Heart Failure*, 2 (6), pp. 641-649.

- von Lueder, T.G., Sangaralingham, S.J., Wang, B.H.  
**Renin-angiotensin blockade combined with natriuretic peptide system augmentation: Novel therapeutic concepts to combat heart failure**  
(2013) *Circ. Heart Fail.*, 6, pp. 594-605.
- Solomon, S.D., Zile, M., Pieske, B.  
**The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial**  
(2012) *Lancet*,  
Available at
- Jessup, M.  
**Neprilysin Inhibition a novel therapy for heart failure**  
(2014) *N. Engl. J. Med.*, 371, p. 11.
- von Lueder, T.G., Wang, B.H., Kompa, A.R., Huang, L., Webb, R., Jordaan, P., Atar, D., Krum, H.  
**The Angiotensin-receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy**  
(2014) *Circ. Heart Fail.*,
- Deddish, P.A., Marcic, B.M., Tan, F., Jackman, H.L., Chen, Z., Erdös, E.G.  
**Neprilysin inhibitors potentiate effects of bradykinin on B2 receptor**  
(2002) *Hypertension*, 39, pp. 619-623.
- Parminder, J., Richard, H., Martin, J., Colin, B.  
**Neprilysin inhibition in chronic kidney disease**  
(2014) *Nephrol. Dial. Transplant.*, pp. 1-6.
- Isaac, R.E., Johnson, E.C., Audsley, N., Shirras, A.D.  
**Metabolic inactivation of the circadian transmitter, pigment dispersing factor (PDF), by neprilysin-like peptidases in Drosophila**  
(2007) *J. Exp. Biol.*, 210, pp. 4465-4470.
- Marr, R.A., Rockenstein, E., Mukherjee, A., Kindy, M.S., Hersh, L.B., Gage, F.H., Verma, I.M., Masliah, E.  
**Neprilysin gene transfer reduces human amyloid pathology in transgenic mice**  
(2003) *J. Neurosci.*, 23 (6), pp. 1992-1996.
- Meilandt, W.J., Cisse, M., Ho, K., Wu, T., Esposito, L.A., Searce, K., Cheng, I.H., Mucke, L.  
**Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic A $\beta$  oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice**  
(2009) *J. Neurosci.*, 29 (7), pp. 1977-1986.
- Spencer, B., Verma, I., Desplats, P., Morvinski, D., Rockenstein, E., Adame, A., Masliah, E.  
**A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates alzheimer disease. Pathology and restores neurogenesis**  
(2014) *J. Biol. Chem*, 289 (25), pp. 17917-17931.

- Joseph, L., Dion, H., Yan, J., Kudsia, H., Jack, H.  
**Efficacy of LCZ696, an angiotensin receptor-neprilysin inhibitor (ARNI) in patients with stage 1-2 systolic hypertension**  
(2014) *JASH*, 8 (4), pp. 27-34.
- Helisalimi, S., Hiltunen, M., Vepsäläinen, S., Iivonen, S., Mannermaa, A., Lehtovirta, M., Koivisto, A.M., Soininen, H.  
**Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients**  
(2004) *J. Neurol. Neurosurg. Psych.*, 75, pp. 1746-1748.

**Адрес для корреспонденции**

Mohammad B.I.; College of Pharmacy, University of Al QadisiyahIraq; эл. почта: jumabassim@yahoo.co.uk

**Издатель:** Nova Science Publishers, Inc.

**ISBN:** 9781634856744; 9781634856461

**Язык оригинального документа:** English

**Сокращенное название источника:** Current Trends in Cardiovascular Research  
2-s2.0-85019911741

**Тип документа:** Book Chapter

**Источник:** Scopus

---

**ELSEVIER**

Авторские права © 2018 Elsevier B.V. Все права защищены. Scopus® является зарегистрированным товарным знаком Elsevier B.V.

 **RELX Group™**